The New Process Validation Paradigm - Ispe Bost... Apr 2026

It aligns with ICH Q8, Q9, and Q10 guidelines, facilitating smoother inspections and global compliance. Conclusion

The New Process Validation Paradigm represents a move toward a more "proactive" pharmaceutical quality system. By treating validation as an ongoing journey rather than a destination, the industry ensures a more reliable supply of safe, effective medicines for patients. The New Process Validation Paradigm - ISPE Bost...

The traditional approach to process validation, once viewed as a one-time "three-batch" hurdle, has undergone a fundamental shift toward a science-based, lifecycle approach. This new paradigm, championed by the ISPE and regulatory bodies like the FDA, emphasizes that quality cannot be tested into a product; it must be built in by design. The Lifecycle Framework It aligns with ICH Q8, Q9, and Q10

Data-driven insights allow for process optimization and reduced waste. The traditional approach to process validation, once viewed

Perhaps the most critical shift, CPV requires ongoing monitoring during routine production. By using statistical process control (SPC), manufacturers can detect drifts or trends before they lead to failures, ensuring the process remains in a state of control throughout its entire commercial life. Why It Matters

Early identification of variability prevents costly batch failures.

The new paradigm is structured into three distinct stages that move away from static documentation toward continuous learning: